Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 16714-484

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 16714-484). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rx Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Divalproex Fig1)

Figure 1 (Divalproex Fig1)
This is a figure showing the reduction in CPS rate of patients receiving Divalproex Sodium Delayed-Release Tablets compared to placebo. The figure depicts that 50% of patients showed improvement in their condition while some showed no change or worsening. There is no further information available in the text.*
FDA Label Image

Figure 2 (Divalproex Fig2)

Figure 2 (Divalproex Fig2)
The text describes a figure labeled as Figure 2 that shows the percentage reduction in CPS rate for patients taking high and low doses of Divalproex Sodium Delayed-Release Tablets. The figure shows that 50% of patients had shown improvement while some patients had shown No change or worsening of their conditions.*
FDA Label Image

Fig-3 (Divalproex Fig3)

Fig-3 (Divalproex Fig3)
This is a list of some numerical values and a medication name "Divalproex Sodium Extended-Release Tablets", but there is not enough context to provide a useful description.*
FDA Label Image

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))

Package Label-principal Display Panel (250 mg (100 Tablets Bottle))
This is a description of a medication for oral administration, in the form of a film-coated tablet. It contains Divalproex sodium, which is equivalent to valproic acid, at a concentration of 250mg. The medication has extended release properties and is to be taken once daily, with dosage instructions provided in an enclosed document. The medication should be stored between 20-25°C (68-77°F), dispensed in a tightly sealed container, and not accepted if the bottle seal is broken or missing. The medication should be accompanied by a medication guide which is available through a phone number, and the tablets are manufactured by Aurobindo Pharma Limited. The size of the tablets is 130 x 50 mm, and NDC code is 16714-484-01.*
FDA Label Image

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))

Package Label-principal Display Panel (500 mg (100 Tablets Bottle))
This is a medication for which each extended-release tablet contains 500 mg of Divalproex sodium USP equivalent to Valproic acid. The recommended dosage can be found in the enclosure provided with the medication. The drug is manufactured by Aurobindo Pharma Limited in Mahabubnagar, India, and distributed by Northstar Rx LLC in Memphis, TN. The tablets should be kept in a tightly sealed, light-resistant container at room temperature. A Medication Guide is provided separately to each patient and pharmacists should dispense it with the medication.*
FDA Label Image

Chemical Structure (Divalproex Str)

Chemical Structure (Divalproex Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.